EUVIMEDEUVIMED entdecken
Crossref

Identifying Early-Phase Clinical Trial Participants at Risk for Experiencing Worse Clinical Outcomes

Debra M Lundquist iD, Rachel Jimenez iD, Sienna Durbin iD, Nora Horick, Megan Healy, Andrew Johnson iD, Viola Bame, Virginia Capasso iD, Casandra McIntyre iD, Barbara Cashavelly, Dejan Juric iD, Ryan D Nipp iD

JCO Oncology Practice · 2023-06 · 19 (6) · e829-e837

DOI: 10.1200/op.22.00742 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2023-06. Verfasst von Debra M Lundquist und 11 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To identify early-phase clinical trial (EP-CT) participants at risk for experiencing worse clinical outcomes and describe receipt of supportive care services. METHODS: A retrospective review of the electronic health records of consecutive patients enrolled in EP-CTs from 2017 to 2019 examined baseline characteristics, clinical outcomes, and receipt of supportive care services. The validated Royal Marsden Hospital (RMH) prognosis score was calculated using data at the time of EP-CT enrollment (scores range from 0 to 3; scores ≥ 2 indicate poor prognosis). Differences in patient characteristics, clinical outcomes, and receipt of supportive care services were compared on the basis of RMH scores. RESULTS: Among 350 patients (median age = 63.2 years [range, 23.0-84.3 years], 57.1% female, 98.0% metastatic cancer), 31.7% had an RMH score indicating a poor prognosis. Those with poor prognosis RMH scores had worse overall survival (hazard ratio [HR], 2.00; P < .001), shorter time on trial (HR, 1.53; P < .001), and lower likelihood of completing the dose-limiting toxicity period (odds ratio, 0.42; P = .006) versus those with good prognosis scores. Patients with poor prognosis scores had greater risk of emergency room visits (HR, 1.66; P = .037) and hospitalizations (HR, 1.69; P = .016) while on trial, and earlier hospice enrollment (HR, 2.22; P = .006). Patients with poor prognosis scores were significantly more likely to receive palliative care consultation (46.8% v 27.6%; P < .001), but not other supportive care services. CONCLUSION: This study found that RMH prognosis score could identify patients at risk for decreased survival, shorter time on trial, and greater use of health care services. The findings underscore the need to develop supportive care interventions targeting EP-CT participants' distinct needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsFemaleHumansMaleMiddle AgedPrognosisProportional Hazards ModelsRetrospective StudiesTreatment OutcomeYoung AdultAdultAgedAged, 80 and overClinical Trials as Topic

Autor:innen und Institutionen

  • Cancer Center Protocol Office, Massachusetts General Hospital, Boston, MA.
  • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA.
  • Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
  • Biostats Center, Massachusetts General Hospital, Boston, MA.
  • Department of Nursing & Patient Care Services, Massachusetts General Hospital, Boston, MA.
  • University of Oklahoma Stephenson Cancer Center, Oklahoma City, OK.

ORCID-Profile: Debra M Lundquist, Rachel Jimenez, Sienna Durbin, Andrew Johnson, Virginia Capasso, Casandra McIntyre, Dejan Juric, Ryan D Nipp

Zitieren

APA

Lundquist, D. M., Jimenez, R., Durbin, S., Horick, N., Healy, M., Johnson, A., Bame, V., Capasso, V., McIntyre, C., Cashavelly, B., Juric, D., & Nipp, R. D. (2023). Identifying Early-Phase Clinical Trial Participants at Risk for Experiencing Worse Clinical Outcomes. JCO Oncology Practice, 19(6), e829-e837. https://doi.org/10.1200/op.22.00742

Vancouver

Lundquist DM, Jimenez R, Durbin S, Horick N, Healy M, Johnson A, et al. Identifying Early-Phase Clinical Trial Participants at Risk for Experiencing Worse Clinical Outcomes. JCO Oncology Practice. 2023;19(6):e829-e837. doi:10.1200/op.22.00742

BibTeX
@article{Lundquist2023,
  author = {Lundquist, Debra M and Jimenez, Rachel and Durbin, Sienna and Horick, Nora and Healy, Megan and Johnson, Andrew and Bame, Viola and Capasso, Virginia and McIntyre, Casandra and Cashavelly, Barbara and Juric, Dejan and Nipp, Ryan D},
  title = {Identifying Early-Phase Clinical Trial Participants at Risk for Experiencing Worse Clinical Outcomes},
  journal = {JCO Oncology Practice},
  year = {2023},
  volume = {19},
  number = {6},
  pages = {e829--e837},
  doi = {10.1200/op.22.00742}
}
Kostenlos starten →